Questions regarding the safety and duration of immunity following live yellow fever vaccination

References

• Russell MN, Cetron MS, Eidex RB. The US-certified yellow fever vaccination center registry: a tool for travelers, state health departments, and vaccine providers. J Travel Med. 2006;13(1):48–49.
   PubMed Web of Science ®Google Scholar
• Monath TP, Vasconcelos PF. Yellow fever. J Clin Virol. 2015;64:160–173.
   PubMed Web of Science ®Google Scholar
• Camara FP, De Carvalho LM, Gomes AL. Demographic profile of sylvatic yellow fever in Brazil from 1973 to 2008. Trans R Soc Trop Med Hyg. 2013;107(5):324–327.
   PubMed Web of Science ®Google Scholar
• Collaborative Group for Studies on Yellow Fever Vaccines. A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old. Mem Inst Oswaldo Cruz. 2015;110(6):771–780.
   PubMed Web of Science ®Google Scholar
• Camacho LA, Freire Mda S, Leal Mda L, et al. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev Saude Publica. 2004;38(5):671–678.
   PubMed Web of Science ®Google Scholar
• Nascimento Silva JR, Camacho LA, Siqueira MM, et al. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine. 2011;29(37):6327–6334.
   PubMed Web of Science ®Google Scholar
• Monath TP. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines. 2012;11(4):427–448.
   PubMed Web of Science ®Google Scholar
• Engel AR, Vasconcelos PF, McArthur MA, et al. Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. Vaccine. 2006;24(15):2803–2809.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Vaccines and vaccination against yellow fever. WHO position paper – June 2013. Wkly Epidemiol Record. 2013;88(27):269–283.
   PubMedGoogle Scholar
• World Health Organization. Background paper on yellow fever vaccine. In: SAGE Working Group, editor. Vaccine position papers. Geneva (Switzerland): SAGE Working Group; 2013.
   Google Scholar
• Centers for Disease Control and Prevention. Grading of recommendations, assessment, development, and evaluation (GRADE) for yellow fever vaccine booster doses. In: US Department of Health and Human Services, CDC, editor. GRADE evidence tables - recommendations in MMWR. Atlanta (GA); 2015.
   Google Scholar
• Staples JE, Bocchini JA Jr, Rubin L, et al. Yellow fever vaccine booster doses: recommendations of the advisory committee on immunization practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(23):647–650.
   PubMed Web of Science ®Google Scholar
• Collaborative Group for Studies on Yellow Fever Vaccines. Duration of post-vaccination immunity against yellow fever in adults. Vaccine. 2014;32(39):4977–4984.
   PubMed Web of Science ®Google Scholar
• Patel D, Simons H. Yellow fever vaccination: is one dose always enough? Travel Med Infect Dis. 2013;11(5):266–273.
   PubMed Web of Science ®Google Scholar
• Grobusch MP, Goorhuis A, Wieten RW, et al. Yellow fever revaccination guidelines change – a decision too feverish? Clin Microbiol Infect. 2013;19(10):885–886.
   PubMed Web of Science ®Google Scholar
• Domingues CMAS. Parecer No. 05/CGPNI/DEVIT/SVS/MS. Recomendações de vacinação contra febre amarela para viajantes, após a declaração da Organização Mundial da Saúde [Recommendations of yellow fever vaccination for travelers, following a statement of the World Health Organization]. Brasília: Ministério da Saúde, Departamento de Vigilância das Doenças Transmissíveis; 2015.
   Google Scholar
• Maranhão AGK. Nota informativa No. 143/CGPNI/DEVIT/SVS/MS. Recomendações da vacinação contra febre amarela, após a declaração da Organização Mundial da Saúde [Recommendations of vaccination against yellow fever, following a statement of the World Health Organization]. Brasília: Ministério da Saúde, Departamento de Vigilância das Doenças Transmissíveis; 2014.
   Google Scholar
• Querec T, Bennouna S, Alkan S, et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med. 2006;203(2):413–424.
   PubMed Web of Science ®Google Scholar
• Querec TD, Akondy RS, Lee EK, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol. 2009;10(1):116–125.
   PubMed Web of Science ®Google Scholar
• Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol. 2009;9(10):741–747.
   PubMed Web of Science ®Google Scholar
• Kohler S, Bethke N, Bothe M, et al. The early cellular signatures of protective immunity induced by live viral vaccination. Eur J Immunol. 2012;42(9):2363–2373.
   PubMed Web of Science ®Google Scholar
• Miller JD, Van Der Most RG, Akondy RS, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity. 2008;28(5):710–722.
   PubMed Web of Science ®Google Scholar
• Akondy RS, Monson ND, Miller JD, et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol. 2009;183(12):7919–7930.
   PubMed Web of Science ®Google Scholar
• James EA, LaFond RE, Gates TJ, et al. Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins. J Virol. 2013;87(23):12794–12804.
   PubMed Web of Science ®Google Scholar
• Blom K, Braun M, Ivarsson MA, et al. Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response. J Immunol. 2013;190(5):2150–2158.
   PubMed Web of Science ®Google Scholar
• Schulz AR, Malzer JN, Domingo C, et al. Low thymic activity and dendritic cell numbers are associated with the immune response to primary viral infection in elderly humans. J Immunol. 2015;195:4699–4711.
   PubMed Web of Science ®Google Scholar
• Niedrig M, Lademann M, Emmerich P, et al. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health. 1999;4(12):867–871.
   PubMed Web of Science ®Google Scholar
• Poland JD, Calisher CH, Monath TP, et al. Persistence of neutralizing antibody 30–35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ. 1981;59(6):895–900.
   PubMed Web of Science ®Google Scholar
• Monath TP, Gershman M, Staples JE, et al. Yellow fever vaccine. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. Philadelphia (PA): Saunders/Elsevier; 2013. p. 870–968.
   Google Scholar
• Reinhardt B, Jaspert R, Niedrig M, et al. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol. 1998;56(2):159–167.
   PubMed Web of Science ®Google Scholar
• Guirakhoo F, Kitchener S, Morrison D, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin. 2006;2(2):60–67.
   PubMed Web of Science ®Google Scholar
• Monath TP, McCarthy K, Bedford P, et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine. 2002;20(7–8):1004–1018.
   PubMed Web of Science ®Google Scholar
• Amanna IJ, Slifka MK. Wanted, dead or alive: new viral vaccines. Antiviral Res. 2009;84(2):119–130.
   PubMed Web of Science ®Google Scholar
• Slifka MK. Vaccine-mediated immunity against dengue and the potential for long-term protection against disease. Front Immunol. 2014;5(195):1–7.
   PubMed Web of Science ®Google Scholar
• Sawyer WA. Persistence of yellow fever immunity. J Prev Med. 1931;5:413–428.
   Google Scholar
• Thibodeaux BA, Garbino NC, Liss NM, et al. A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model. Antiviral Res. 2012;94(1):1–8.
   PubMed Web of Science ®Google Scholar
• Julander JG, Trent DW, Monath TP. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine. 2011;29(35):6008–6016.
   PubMed Web of Science ®Google Scholar
• Mason RA, Tauraso NM, Spertzel RO, et al. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol. 1973;25(4):538–544.
   Google Scholar
• Dick GW, Gee FL. Immunity to yellow fever nine years after vaccination with 17D vaccine. Trans R Soc Trop Med Hyg. 1952;46(4):449–458.
   PubMed Web of Science ®Google Scholar
• De Melo AB, Da Silva Mda P, Magalhaes MC, et al. Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil. Am J Trop Med Hyg. 2011;85:739–747.
   PubMed Web of Science ®Google Scholar
• Machado VW, Vasconcelos PF, Silva EV, et al. Serologic assessment of yellow fever immunity in the rural population of a yellow fever-endemic area in Central Brazil. Rev Soc Bras Med Trop. 2013;46(2):166–171.
   PubMed Web of Science ®Google Scholar
• Rosenzweig EC, Babione RW, Wisseman CL Jr. Immunological studies with group B arthropod-borne viruses. IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine. Am J Trop Med Hyg. 1963;12:230–235.
   PubMed Web of Science ®Google Scholar
• Courtois G. [Duration of immunity after yellow fever vaccination]. Ann Soc Belg Med Trop. 1954;34(1):9–12.
   Google Scholar
• Groot H, Riberiro RB. Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine. Bull World Health Organ. 1962;27:699–707.
   PubMed Web of Science ®Google Scholar
• Gomez SY, Ocazionez RE. Yellow fever virus 17D neutralising antibodies in vaccinated Colombian people and unvaccinated ones having immunity against dengue. Rev Salud Publica (Bogota). 2008;10(5):796–807.
   PubMedGoogle Scholar
• Coulange Bodilis H, Benabdelmoumen G, Gergely A, et al. Long term persistence of yellow fever neutralising antibodies in elderly persons. Bull Soc Pathol Exot. 2011;104(4):260–265.
   PubMedGoogle Scholar
• Hepburn MJ, Kortepeter MG, Pittman PR, et al. Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine. Vaccine. 2006;24:2843–2849.
   PubMed Web of Science ®Google Scholar
• Edghill-Smith Y, Golding H, Manischewitz J, et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med. 2005;11:740–747.
   PubMed Web of Science ®Google Scholar
• Hammarlund E, Lewis MW, Hansen SG, et al. Duration of antiviral immunity after smallpox vaccination. Nature Medicine. 2003;9(9):1131–1137.
   PubMed Web of Science ®Google Scholar
• Crotty S, Felgner P, Davies H, et al. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol. 2003;171(10):4969–4973.
   PubMed Web of Science ®Google Scholar
• Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007;357(19):1903–1915.
   PubMed Web of Science ®Google Scholar
• Frey SE, Wald A, Edupuganti S, et al. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naive subjects. Vaccine. 2015;33(39):5225–5234.
   PubMed Web of Science ®Google Scholar
• Von Krempelhuber A, Vollmar J, Pokorny R, et al. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine. 2010;28(5):1209–1216.
   PubMed Web of Science ®Google Scholar
• Beck AS, Barrett AD. Current status and future prospects of yellow fever vaccines. Expert Rev Vaccines. 2015;14(11):1479–1492.
   PubMed Web of Science ®Google Scholar
• Doblas A, Domingo C, Bae HG, et al. Yellow fever vaccine-associated viscerotropic disease and death in Spain. J Clin Virol. 2006;36:156–158.
   PubMed Web of Science ®Google Scholar
• Akondy RS, Johnson PL, Nakaya HI, et al. Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination. Proc Natl Acad Sci U S A. 2015;112(10):3050–3055.
   PubMed Web of Science ®Google Scholar
• Domingo C, Yactayo S, Agbenu E, et al. Detection of yellow fever 17D genome in urine. J Clin Microbiol. 2011;49(2):760–762.
   PubMed Web of Science ®Google Scholar
• Hammarlund E, Lewis MW, Hanifin JM, et al. Traditional smallpox vaccination with reduced risk of inadvertent contact spread by administration of povidone iodine ointment. Vaccine. 2008;26(3):430–439.
   PubMed Web of Science ®Google Scholar
• Monath TP, Nichols R, Archambault WT, et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg. 2002;66(5):533–541.
   PubMed Web of Science ®Google Scholar
• Veit O, Niedrig M, Chapuis-Taillard C, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis. 2009;48:659–666.
   PubMed Web of Science ®Google Scholar
• Monath TP. Dengue and yellow fever–challenges for the development and use of vaccines. N Engl J Med. 2007;357:2222–2225.
   PubMed Web of Science ®Google Scholar
• Lindsey NP, Schroeder BA, Miller ER, et al. Adverse event reports following yellow fever vaccination. Vaccine. 2008;26:6077–6082.
   PubMed Web of Science ®Google Scholar
• Cottin P, Niedrig M, Domingo C. Safety profile of the yellow fever vaccine Stamaril®: a 17-year review. Expert Rev Vaccines. 2013;12(11):1351–1368.
   PubMed Web of Science ®Google Scholar
• Breugelmans JG, Lewis RF, Agbenu E, et al. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010. Vaccine. 2013;31(14):1819–1829.
   PubMed Web of Science ®Google Scholar
• Khromava AY, Eidex RB, Weld LH, et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine. 2005;23:3256–3263.
   PubMed Web of Science ®Google Scholar
• Schumacher Z, Bourquin C, Heininger U. Surveillance for adverse events following immunization (AEFI) in Switzerland–1991–2001. Vaccine. 2010;28:4059–4064.
   PubMed Web of Science ®Google Scholar
• Wattigney WA, Mootrey GT, Braun MM, et al. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Pediatrics. 2001;107(5):E83.
   PubMed Web of Science ®Google Scholar
• Kramarz P, France EK, Destefano F, et al. Population-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis J. 2001;20(4):410–416.
   PubMed Web of Science ®Google Scholar
• Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med. 2001;344(8):564–572.
   PubMed Web of Science ®Google Scholar
• Kelso JM, Mootrey GT, Tsai TF. Anaphylaxis from yellow fever vaccine. J Allergy Clin Immunol. 1999;103:698–701.
   PubMed Web of Science ®Google Scholar
• Bohlke K, Davis RL, Marcy SM, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics. 2003;112(4):815–820.
   PubMed Web of Science ®Google Scholar
• Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine. 2004;22(17–18):2103–2105.
   PubMed Web of Science ®Google Scholar
• Fernandes GC, Camacho LA, Sa Carvalho M, et al. Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999–2005. Vaccine. 2007;25:3124–3128.
   PubMed Web of Science ®Google Scholar
• Guimard T, Minjolle S, Polard E, et al. Short report: Incidence of yellow fever vaccine-associated neurotropic disease. Am J Trop Med Hyg. 2009;81:1141–1143.
   PubMed Web of Science ®Google Scholar
• Prevots DR, Sutter RW, Strebel PM, et al. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Implications for estimating the risk of vaccine-associated disease. Arch Pediatr Adolesc Med. 1994;148(5):479–485.
   PubMedGoogle Scholar
• Hao L, Toyokawa S, Kobayashi Y. Poisson-model analysis of the risk of vaccine-associated paralytic poliomyelitis in Japan between 1971 and 2000. Jpn J Infect Dis. 2008;61(2):100–103.
   PubMed Web of Science ®Google Scholar
• Whittembury A, Ramirez G, Hernandez H, et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine. 2009;27:5974–5981.
   PubMed Web of Science ®Google Scholar
• Miller ER, Moro PL, Cano M, et al. Deaths following vaccination: what does the evidence show? Vaccine. 2015;33(29):3288–3292.
   PubMed Web of Science ®Google Scholar
• Zanardi LR, Haber P, Mootrey GT, et al. Intussusception among recipients of rotavirus vaccine: reports to the vaccine adverse event reporting system. Pediatrics. 2001;107(6):E97.
   PubMed Web of Science ®Google Scholar
• Biscayart C, Carrega ME, Sagradini S, et al. Yellow fever vaccine-associated adverse events following extensive immunization in Argentina. Vaccine. 2014;32(11):1266–1272.
   PubMed Web of Science ®Google Scholar
• Fitzner J, Coulibaly D, Kouadio DE, et al. Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast. Vaccine. 2004;23:156–162.
   PubMed Web of Science ®Google Scholar
• Stuart G. Reactions following vaccination against yellow fever. In: World Health Organization, editor. Yellow fever vaccination. Geneva (Switzerland): WHO; 1956. p. 143– 189.
   Google Scholar
• YF-VAX® Package Insert. Swiftwater (PA): Sanofi Pasteur; 2013. Rev. 2013 May 2.
   Google Scholar
• Staples JE, Gershman M, Fischer M. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59:1–27.
   PubMedGoogle Scholar
• Sencer DJ, Langmuir AD, Kokko UP, et al. Fatal viral encephalitis following 17D yellow fever vaccine inoculation. Report of a case in a 3-year-old child. Jama. 1966;198(6):671–672.
   PubMed Web of Science ®Google Scholar
• Jennings AD, Gibson CA, Miller BR, et al. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J Infect Dis. 1994;169(3):512–518.
   PubMed Web of Science ®Google Scholar
• Martins Rde M, Pavao AL, De Oliveira PM, et al. Adverse events following yellow fever immunization: report and analysis of 67 neurological cases in Brazil. Vaccine. 2014;32(49):6676–6682.
   PubMed Web of Science ®Google Scholar
• Martins Rde M, Maia Mde L, Dos Santos EM, et al. Yellow fever vaccine post-marketing surveillance in Brazil. Proc Vaccinol. 2010;2:178–183.
   Google Scholar
• Vasconcelos PF, Luna EJ, Galler R, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet. 2001;358:91–97.
   PubMed Web of Science ®Google Scholar
• Rafferty E, Duclos P, Yactayo S, et al. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review. Vaccine. 2013;31(49):5798–5805.
   PubMed Web of Science ®Google Scholar
• Seligman SJ. Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Vaccine. 2014;32(44):5769–5775.
   PubMed Web of Science ®Google Scholar
• Monath TP. Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States. Am J Trop Med Hyg. 2010;82:919–921.
   PubMed Web of Science ®Google Scholar
• Thomas RE, Lorenzetti DL, Spragins W, et al. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review. Vaccine. 2011;29:4544–4555.
   PubMed Web of Science ®Google Scholar
• Cetron MS, Marfin AA, Julian KG, et al. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep. 2002;51(RR–17):1–11.
   PubMedGoogle Scholar
• Fox JP, Lennette EH, Manso C, et al. Encephalitis in man following vaccination with 17D yellow fever virus. Amer J Hyg. 1942;36(2):117–142.
   Google Scholar
• WHO Expert Committee on Biological Standardization. Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines. In: World Health Organization, editor. WHO expert committee on biological standardization. Geneva (Switzerland): WHO; 2012. p. 241–314.
   Google Scholar
• Advisory Committee on Immunization Practices. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(RR–3):1–25.
   Google Scholar
• World Health Organization. Evidence on the safety and efficacy of live poliomyelitis vaccines currently in use, with special reference to type 3 poliovirus. Bull World Health Organ. 1969;40(6):925–945.
   PubMed Web of Science ®Google Scholar
• Advisory Committee on Immunization Practices. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49(RR–5):1–22.
   Google Scholar
• Walton LR, Orenstein WA, Pickering LK. Lessons learned from making and implementing vaccine recommendations in the U.S. Vaccine. 2015;33(Suppl 4):D78–82.
   PubMed Web of Science ®Google Scholar
• Hayes EB. Is it time for a new yellow fever vaccine? Vaccine. 2010;28(51):8073–8076.
   PubMed Web of Science ®Google Scholar
• Monath TP, Cetron MS. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis. 2002;34:1369–1378.
   PubMed Web of Science ®Google Scholar
• Plotkin SL, Plotkin SA. A short history of vaccination. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. Philadelphia (PA): Saunders/Elsevier; 2008. p. 1–16.
   Google Scholar
• Black S. The role of health economic analyses in vaccine decision making. Vaccine. 2013;31(51):6046–6049.
   PubMed Web of Science ®Google Scholar
• Thompson KM, Tebbens RJ. Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Anal. 2006;26:1423–1440.
   PubMed Web of Science ®Google Scholar
• Miller MA, Sutter RW, Strebel PM, et al. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. JAMA. 1996;276(12):967–971.
   PubMed Web of Science ®Google Scholar
• Monath TP, Lee CK, Julander JG, et al. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine. 2010;28:3827–3840.
   PubMed Web of Science ®Google Scholar
• Amanna IJ, Raue HP, Slifka MK. Development of a new hydrogen peroxide-based vaccine platform. Nat Med. 2012;18(6):974–979.
   PubMed Web of Science ®Google Scholar
• Gaspar LP, Mendes YS, Yamamura AM, et al. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development. J Virol Methods. 2008;150:57–62.
   PubMed Web of Science ®Google Scholar
• Monath TP, Fowler E, Johnson CT, et al. An inactivated cell-culture vaccine against yellow fever. N Engl J Med. 2011;364(14):1326–1333.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Immunization, Vaccines and Biologicals - African Region. Geneva; 2015. Available from: http://www.who.int/immunization/monitoring_surveillance/data/AFR/en/
   Google Scholar
• Slifka MK, Amanna I. How advances in immunology provide insight into improving vaccine efficacy. Vaccine. 2014;32(25):2948–2957.
   PubMed Web of Science ®Google Scholar
• Safaeian M, Porras C, Pan Y, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila). 2013;6(11):1242–1250.
   PubMed Web of Science ®Google Scholar
• Bovier PA, Bock J, Ebengo TF, et al. Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine. J Med Virol. 2010;82(10):1629–1634.
   PubMed Web of Science ®Google Scholar